Bio-Rad Laboratories (BIO) Current Deferred Revenue (2010 - 2022)

Bio-Rad Laboratories (BIO) has reported Current Deferred Revenue for 13 consecutive years, with $71.9 million the latest figure, recorded in Q4 2022.

• On a quarterly basis, Current Deferred Revenue rose 1.27% year-over-year to $71.9 million in Q4 2022; TTM through Dec 2022 was $71.9 million, a 1.27% increase from a year earlier, with the FY2022 full-year figure at $71.9 million, up 1.27% from the prior year.
• Current Deferred Revenue was $71.9 million for Q4 2022 at Bio-Rad Laboratories, up from $71.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $71.9 million in Q4 2022 and troughed at $37.3 million in Q4 2018.
• A 5-year average of $49.1 million and a median of $45.6 million in 2019 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue surged 31.0% in 2020 and increased 1.27% in 2022, its largest moves.
• Over 5 years, Current Deferred Revenue stood at $37.3 million in 2018, then rose by 22.79% to $45.8 million in 2019, then surged by 31.0% to $60.0 million in 2020, then rose by 18.33% to $71.0 million in 2021, then climbed by 1.27% to $71.9 million in 2022.
• The last three Current Deferred Revenue figures came in at $71.9 million (Q4 2022), $71.0 million (Q4 2021), and $60.0 million (Q4 2020), per Business Quant data.